Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
To find expiration dates for patents on chemotherapy medicines
— Program manager, non-profit, USA
To apply for a patent
— Pharmaceutical researcher, USA
To find examples of compounds losing patent protection in 2016-2019
— Researcher, Poland
To get a list of drugs going off patent in USA in the next few years
— Pharmaceutical sales, India
To find drug patent expirations in the North Africa market
— Business development, India
Generated: May 22, 2017
| Title: | Use of 1.alpha.-hydroxylated-19-nor-vitamin D compounds to treat psoriasis |
| Abstract: | A novel use for 1.alpha.-hydroxylated-19-nor-vitamin D compounds to treat psoriasis inasmuch as these compounds when administered to humans are converted to a metabolite, such as a 1.alpha.,25-dihydroxylated compound, which metabolite in vitro will cause differentiation in a human cell line. |
| Inventor(s): | DeLuca; Hector F. (Deerfield, WI) |
| Assignee: | Wisconsin Alumni Research Foundation (Madison, WI) |
| Filing Date: | Nov 20, 1992 |
| Application Number: | 07/987,258 |
| Claims: | 1. A method for treating psoriasis which comprises administering to a patient an effective amount of a compound of the formula: ##STR9## where X and Y are each selected from the group consisting of hydrogen, acyl, alkylsilyl and alkoxyalkyl, and where U is selected from a side chain of the formula ##STR10## wherein R.sub.1 and R.sub.2 are each selected from the group consisting of alkyl, deuteroalkyl, hydroxyalkyl and fluoroalkyl, or, when taken together represent the group--(CH.sub.2).sub.m --where m is an integer having a value of from 2 to 5, R.sub.3 is selected from the group consisting of hydrogen, deuterium, hydroxy, fluorine, O-acyl, alkyl, hydroxyalkyl and fluoroalkyl, R.sub.6 is selected from the group consisting of hydrogen, deuterium, fluorine, alkyl, hydroxyalkyl and fluoroalkyl, or, R.sub.3 and R.sub.6 taken together represent double-bonded oxygen or double-bonded carbon, R.sub.4 and R.sub.5 are each selected from the group consisting of hydrogen, deuterium, hydroxy, O-acyl, fluorine and alkyl, or, R.sub.4 and R.sub.5 taken together form a carbon-carbon double bond or a carbon-carbon triple bond, and wherein n is an integer having a value of from 1 to 5 and wherein the carbon at any one of positions 20, 22, or 23 in the side chain may be replaced by an O, S, or N atom with the proviso that when n is 1 then R.sub.1 and R.sub.2 must both be methyl. 2. The method of claim 1 wherein said compound is 1.alpha.-hydroxy-19-nor-vitamin D.sub.3. 3. The method of claim 1 wherein said compound is 1.alpha.-hydroxy-19-nor-24,24-difluoro-vitamin D.sub.3. 4. The method of claim 1 wherein said compound is 1.alpha.-hydroxy-19-nor-26,27-hexadeutero-vitamin D.sub.3. 5. The method of claim 1 wherein said compound is 1.alpha.-hydroxy-19-nor-26,27-hexafluorovitamin D.sub.3. 6. The method of claim 1 wherein said compound is 1.alpha.-hydroxy-19-nor-vitamin D.sub.2. 7. The method of claim 1 wherein the compound is 24-homo-1.alpha.-hydroxy-19-nor-22-dehydrovitamin D.sub.3. 8. The method of claim 1 wherein the compound is 24-dihomo-1.alpha.-hydroxy-19-nor-22-dehydrovitamin D.sub.3. 9. The method of claim 1 wherein the compound is 24-trihomo-1.alpha.-hydroxy-19-nor-22-dehydrovitamin D.sub.3. 10. The method of claim 1 wherein the compound is 26,27-dimethyl-24-dihomo-1.alpha.-hydroxy-19-nor-22-dehydrovitamin D.sub.3. 11. The method of claim 1 wherein the compound is 26,27-dimethyl-24-trihomo-1.alpha.-hydroxy-19-nor-22-dehydrovitamin D.sub.3. 12. The method of claim 1 wherein the compound is 26,27-diethyl-24-dihomo-1.alpha.-hydroxy-19-nor-22-dehydrovitamin D.sub.3. 13. The method of claim 1 wherein the compound is 26,27-diethyl-24-trihomo-1.alpha.-hydroxy-19-nor-22-dehydrovitamin D.sub.3. 14. The method of claim 1 wherein the compound is 26,27-dipropyl-24-dihomo-1.alpha.-hydroxy-19-nor-22-dehydrovitamin D.sub.3. 15. The method of claim 1 wherein the compound is 26,27-dipropyl-24-trihomo-1.alpha.-hydroxy-19-nor-22-dehydrovitamin D.sub.3. 16. The method of claim 1 wherein the compound is 24-homo-1.alpha.-hydroxy-19-nor-vitamin D.sub.3. 17. The method of claim 1 wherein the compound is 24-dihomo-1.alpha.-hydroxy-19-nor-vitamin D.sub.3. 18. The method of claim 1 wherein the compound is 24-trihomo-1.alpha.-hydroxy-19-nor-vitamin D.sub.3. 19. The method of claim 1 wherein the compound is 26,27-dimethyl-24-dihomo-1.alpha.-hydroxy-19-nor-vitamin D.sub.3. 20. The method of claim 1 wherein the compound is 26,27-dimethyl-24-trihomo-1.alpha.-hydroxy-19-nor-vitamin D.sub.3. 21. The method of claim 1 wherein the compound is 26,27-diethyl-24-dihomo-1.alpha.hydroxy-19-nor-vitamin D.sub.3. 22. The method of claim 1 wherein the compound is 26,27-diethyl-24-trihomo-1.alpha.-hydroxy-19-nor-vitamin D.sub.3. 23. The method of claim 1 wherein the compound is 26,27-dipropyl-24-dihomo-1.alpha.-hydroxy-19-nor-vitamin D.sub.3. 24. The method of claim 1 wherein the compound is 26,27-dipropyl-24-trihomo-1.alpha.-hydroxy-19-nor-vitamin D.sub.3. 25. The method of claim 1 wherein the compound is 1.alpha.-hydroxy-19-nor-24 epi-vitamin D.sub.2. 26. The method of claim 1 wherein said effective amount comprises about 0.01 .mu.g/day to about 100 .mu.g/day of said compound. 27. A composition for use in the treatment of psoriasis which comprises an effective amount of a compound of the formula: ##STR11## where X and Y are each selected from the group consisting of hydrogen, acyl, alkylsilyl and alkoxyalkyl, and where U is selected from a side chain of the formula ##STR12## wherein R.sub.1 and R.sub.2 are each selected from the group consisting of alkyl, deuteroalkyl, hydroxyalkyl and fluoroalkyl, or, when taken together represent the group--(CH.sub.2).sub.m --where m is an integer having a value of from 2 to 5, R.sub.3 is selected from the group consisting of hydrogen, deuterium, hydroxy, fluorine, O-acyl, alkyl, hydroxyalkyl and fluoroalkyl, R.sub.6 is selected from the group consisting of hydrogen, deuterium, fluorine, alkyl, hydroxyalkyl and fluoroalkyl, or, R.sub.3 and R.sub.6 taken together represent double-bonded oxygen or double-bonded carbon, R.sub.4 and R.sub.5 are each selected from the group consisting of hydrogen, deuterium, hydroxy, O-acyl, fluorine and alkyl, or, R.sub.4 and R.sub.5 taken together form a carbon-carbon double bond or a carbon-carbon triple bond, and wherein n is an integer having a value of from 1 to 5 and wherein the carbon at any one of positions 20, 22, or 23 in the side chain may be replaced by an O, S, or N atom with the proviso that when n is 1 then R.sub.1 and R.sub.2 must both be methyl. 28. The composition of claim 27 wherein said compound is 1.alpha.-hydroxy-19-nor-vitamin D.sub.3. 29. The composition of claim 27 wherein said compound is 1.alpha.-hydroxy-19-nor-24,24-difluoro-vitamin D.sub.3. 30. The composition of claim 27 wherein said compound is 1.alpha.-hydroxy-19-nor-26,27-hexadeutero-vitamin D.sub.3. 31. The composition of claim 27 wherein said compound is 1.alpha.-hydroxy-19-nor-26,27-hexafluorovitamin D.sub.3. 32. The composition of claim 27 wherein said compound is 1.alpha.-hydroxy-19-nor-vitamin D.sub.2. 33. The composition of claim 27 wherein the compound is 24-homo-1.alpha.-hydroxy-19-nor-22-dehydrovitamin D.sub.3. 34. The composition of claim 27 wherein the compound is 24-dihomo-1.alpha.-hydroxy-19-nor-22-dehydrovitamin D.sub.3. 35. The composition of claim 27 wherein the compound is 24-trihomo-1.alpha.-hydroxy-19-nor-22dehydrovitamin D.sub.3. 36. The composition of claim 27 wherein the compound is 26,27-dimethyl-24-dihomo-1.alpha.-hydroxy-19-nor-22-dehydrovitamin D.sub.3. 37. The composition of claim 27 wherein the compound is 26,27-dimethyl-24-trihomo-1.alpha.-hydroxy-19-nor-22-dehydrovitamin D.sub.3. 38. The composition of claim 27 wherein the compound is 26,27-diethyl-24-dihomo-1.alpha.-hydroxy-19-nor-22-dehydrovitamin D.sub.3. 39. The composition of claim 27 wherein the compound is 26,27-diethyl-24-trihomo-1.alpha.-hydroxy-19-nor-22-dehydrovitamin D.sub.3. 40. The composition of claim 27 wherein the compound is 26,27-dipropyl-24-dihomo-1.alpha.-hydroxy-19-nor22-dehydrovitamin D.sub.3. 41. The composition of claim 27 wherein the compound is 26,27-dipropyl-24-trihomo-1.alpha.-hydroxy-19-nor22-dehydrovitamin D.sub.3. 42. The composition of claim 27 wherein the compound is 24-homo-1.alpha.-hydroxy-19-nor-vitamin D.sub.3. 43. The composition of claim 27 wherein the compound is 24-dihomo-1.alpha.-hydroxy-19-nor-vitamin D.sub.3. 44. The composition of claim 27 wherein the compound is 24-trihomo-1.alpha.-hydroxy-19-nor-vitamin D.sub.3. 45. The composition to claim 27 wherein the compound is 26,27-dimethyl-24-dihomo-1.alpha.-hydroxy-19-nor-vitamin D.sub.3. 46. The composition of claim 27 wherein the compound is 26,27-dimethyl-24-trihomo-1.alpha.-hydroxy-19-nor-vitamin D.sub.3. 47. The composition of claim 27 wherein the compound is 26,27-diethyl-24-dihomo-1.alpha.-hydroxy-19-nor-vitamin D.sub.3. 48. The composition of claim 27 wherein the compound is 26,27-diethyl-24-trihomo-1.alpha.-hydroxy-19-nor-vitamin D.sub.3. 49. The composition of claim 27 wherein the compound is 26,27-dipropyl-24-dihomo-1.alpha.-hydroxy-19-nor-vitamin D.sub.3. 50. The composition of claim 27 wherein the compound is 26,27-dipropyl-24-trihomo-1.alpha.-hydroxy-19-nor-vitamin D.sub.3. 51. The composition of claim 27 wherein the compound is 1.alpha.-hydroxy-19-nor-24 epi-vitamin D.sub.2. 52. The composition of claim 27 wherein said effective amount is between about 0.01 .mu.g to about 100 .mu.g per gram of the composition. 53. A method of treating psoriasis which comprises administering to a patient an effective amount of 1.alpha.-hydroxylated-19-nor-vitamin D compound which compound upon administering to humans is converted to a metabolite and said metabolite in vitro will cause differentiation of promelocytes to monocytes in a cell line selected from a group consisting of a U937 cell line, an HL60 cell line and a M1 cell line. |
To gain knowledge on formulations of different drugs
— Product development officer, Pharmaceutical company, Bangladesh
To get information on when drug patents are set to expire or have expired
— Journalist, UK
To identify the patency situation for APIs worldwide
— Pharmaceutical professional, Egypt
For fast access to patent and market exclusivity
— Senior medical scientific advisor, Germany
To understand various drug patents throughout the world
— Business development manager, India
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639
Follow DrugPatentWatch:
Join the 21,318 other biopharmaceutical professionals who get our Drug Patent Expiration Alerts:
